Daily Stock Opinions and Ratings

Opinions

Jim Cramer - Mad MoneyCorteva Inc.CTVARISKYNov 06, 2026

They report Wednesday. They spun off a company and maybe they can benefit from a new focus. Valuation is cheap.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$11.90

Stock price when the opinion was issued

$9.19

As of Nov 12, 2026. Market Open.

agriculture

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

The chart has been consolidating this year. It could be overbought and could break down and return to support around $78. But if it falls below support, that's not good. Or it could break out. 50/50 call.

BUY

A slow mover, but is in the process of breaking out, though not like a tech stock. Their last report showed operating EBITDA margin +280 basis points, free cash flow +40%, and announced a $1 billion share buyback for this year. RSI is 58, so not overbought. Likes their golden cross.

PAST TOP PICK

(A Top Pick Aug 04/23, Down 3%)

Phenomenal business. Somewhat sensitive to corn prices. Back to a double-digit grower. Rock-solid balance sheet and free cashflow. Unique and great.

TOP PICK

Seed & crop protection company.
Strong demand for agriculture products.
Double digit earnings growth.
Pristine balance sheet with little debt.
Steady dividend that is reliable.
Well run business with excellent management.

DON'T BUY

Is expensive vs. Deere and revenue growth is only 6% over the last three years. The biotech story in agriculture has to be a catalyst to get him excited and that's a stretch.

BUY

The ad market is soggy now, but will come back. He is bullish this long term.

BUY

Nice top and bottom line beat. 11% organic growth driven by strong demand for agricultural commodities.

BUY ON WEAKNESS

They make seeds and pesticides for agriculture, a sector which boomed this year. Corteva sales jumped this year, but will continue in years ahead. This isn't a fertilizer play (which is a trade, not investment). Farmers are and will buy Corteva's genetically modified seeds for the long-term. Despite its good run, CTVA still trades under 19x forward earnings.

Unspecified

It is probably the only crop protection and seeds business that is publicly traded. We need more productive seeds and chemicals in the agricultural business. There is a very low supplies to use ratio. The tight global grain market is due to the Ukraine/Russia conflict so Cortiva is important to the solution of the problem.

BUY

Necessary for food production in times of climate change. Management's done a great job, evolving their portfolio into higher margin businesses and products. Almost a tech company.

BUY

Crop science company, competing with Monsanto but without the social issues. Phenomenal R&D. Unique products. Huge impact in emerging markets. Helps with food security. Very well run, great cashflow generator, pretty good earnings growth. His pick in the sector.

BUY

Was spun off from the Dow-Dupont merger. We're seeing a bull market in the fertilizer market. Corteva's genetically modified seeds produce the best yields in the business. A JPMorgan reports forecasts low agricultural yields and higher demand short-term.

BUY

NTR vs. Corteva He owns both. Cortevais into crop protection. Nutrien is in fertilizer. Both are strongly correlated to commodity prices, however. Nutrien pays a healthy dividend, but Corteva offers better growth and could benefit from ongoing climate change problems. Both are best-in-class businesses.

TOP PICK

They don’t have the Monsanto issues. People don’t want to buy GMO foods but the fact is that it is how we feed places like India and China where people used to die of starvation when there were droughts. He expects earnings growth of 15% for the next few years. It will get better over the next few years. (Analysts’ price target is $32.81)

Most Recent Experts

Stan Wong

Private Wealth Management, ScotiaMcleod